Tirzepatide cuts risk of diabetes by 94% in adults with ... - CNN
Aug 20, 2024 — CNN — A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or...
Mounjaro leads to significantly more weight loss than Ozempic, …
Jul 8, 2024 — People taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study.
FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first …
FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
Eli Lilly's tirzepatide cuts heart failure risks, company says - NBC News
Aug 1, 2024 — Eli Lilly’s drug tirzepatide, sold under the names Mounjaro for diabetes and Zepbound for weight loss, improved symptoms in heart failure patients with obesity, the company said Thursday.
News Release - Eli Lilly and Company
Aug 1, 2024 — Tirzepatide was approved by the FDA as Mounjaro ® for adults with type 2 diabetes to improve glycemic control on May 13, 2022, and as Zepbound ® for adults with obesity (a BMI of 30 kg/m 2 or greater) or those who are overweight (a BMI of 27 kg/m 2 or greater) who also have a weight-related comorbid condition on November 8, 2023. Both ...
A new version of the diabetes drug Mounjaro can ... - Associated Press News
Nov 8, 2023 — The drug, also known as tirzepatide, helped dieters lose as much as 40 to 60 pounds in testing. Zepbound is the latest diabetes drug approved for chronic weight management, joining Novo Nordisk’s Wegovy, a high-dose version of its diabetes treatment Ozempic. Both are weekly injections.
Drug used in diabetes treatment Mounjaro helped ... - Associated Press News
Oct 16, 2023 — The injected drug, tirzepatide, was approved in the U.S. in May 2022 to treat diabetes. Sold as Mounjaro, it has been used “off-label” to treat obesity, joining a frenzy of demand for diabetes and weight-loss medications including Ozempic and Wegovy, made by …
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
Oct 3, 2024 — The Food and Drug Administration on Wednesday declared an end to the two-year shortage of tirzepatide, the substance in the popular weight-loss medication Zepbound and the diabetes drug...
FDA Says Mounjaro, Zepbound Shortage Has Ended: What to Know - Healthline
Aug 7, 2024 — A news release from Eli Lilly in June 2024 outlines some concerns surrounding compounded versions of tirzepatide (the active ingredient in Mounjaro and Zepbound), some of which contained...
News Release - Eli Lilly and Company
Oct 6, 2022 — Tirzepatide was approved as Mounjaro ® (tirzepatide) by the FDA on May 13, 2022. Mounjaro is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.